Barclays’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-7,348
| Closed | -$109K | – | 5451 |
|
|
2024
Q1 | $109K | Sell |
7,348
-7,032
| -49% | -$98.8K | ﹤0.01% | 4402 |
|
|
2023
Q4 | $193K | Buy |
14,380
+12,535
| +679% | +$158K | ﹤0.01% | 4437 |
|
|
2023
Q3 | $22.7K | Sell |
1,845
-3,772
| -67% | -$45.7K | ﹤0.01% | 4148 |
|
|
2023
Q2 | $69.1K | Buy |
5,617
+179
| +3% | +$2.24K | ﹤0.01% | 3706 |
|
|
2023
Q1 | $66.8K | Buy |
5,438
+5,303
| +3,928% | +$62.3K | ﹤0.01% | 4348 |
|
|
2022
Q4 | $1.55K | Buy |
+135
| New | +$1.11K | ﹤0.01% | 5097 |
|
|
2021
Q2 | – | Sell |
-320
| Closed | -$2K | – | 5220 |
|
|
2021
Q1 | $2K | Buy |
+320
| New | +$2.29K | ﹤0.01% | 4577 |
|
|
2020
Q1 | – | Sell |
-8
| Closed | – | – | 6764 |
|
|
2019
Q4 | $0 | Sell |
8
-42
| -84% | -$168 | ﹤0.01% | 7202 |
|
|
2019
Q3 | $0 | Sell |
50
-14
| -22% | -$70 | ﹤0.01% | 7498 |
|
|
2019
Q2 | $0 | Hold |
64
| – | – | ﹤0.01% | 7580 |
|
|
2019
Q1 | $0 | Hold |
64
| – | – | ﹤0.01% | 7652 |
|
|
2018
Q4 | $0 | Sell |
64
-889
| -93% | -$3.08K | ﹤0.01% | 7775 |
|
|
2018
Q3 | $4K | Sell |
953
-22,832
| -96% | -$96.2K | ﹤0.01% | 6861 |
|
|
2018
Q2 | $92K | Buy |
23,785
+20,385
| +600% | +$135K | ﹤0.01% | 5307 |
|
|
2018
Q1 | $21K | Buy |
3,400
+292
| +9% | +$2.42K | ﹤0.01% | 6427 |
|
|
2017
Q4 | $25K | Buy |
3,108
+2,729
| +720% | +$25.4K | ﹤0.01% | 6195 |
|
|
2017
Q3 | $4K | Buy |
379
+252
| +198% | +$2.65K | ﹤0.01% | 6556 |
|
|
2017
Q2 | $1K | Sell |
127
-737
| -85% | -$15.1K | ﹤0.01% | 6590 |
|
|
2017
Q1 | $21K | Sell |
864
-6,624
| -88% | -$166K | ﹤0.01% | 5798 |
|
|
2016
Q4 | $241K | Sell |
7,488
-7,776
| -51% | -$332K | ﹤0.01% | 4066 |
|
|
2016
Q3 | $762K | Buy |
+15,264
| New | +$634K | ﹤0.01% | 2882 |
|
|
2016
Q2 | – | Sell |
-753
| Closed | -$47K | – | 6871 |
|
|
2016
Q1 | $47K | Buy |
753
+518
| +220% | +$27K | ﹤0.01% | 4815 |
|
|
2015
Q4 | $13K | Sell |
235
-3,639
| -94% | -$256K | ﹤0.01% | 5335 |
|
|
2015
Q3 | $244K | Buy |
3,874
+2,451
| +172% | +$200K | ﹤0.01% | 3993 |
|
|
2015
Q2 | $134K | Sell |
1,423
-15,741
| -92% | -$1.5M | ﹤0.01% | 4443 |
|
|
2015
Q1 | $1.49M | Buy |
17,164
+16,123
| +1,549% | +$1.37M | ﹤0.01% | 2597 |
|
|
2014
Q4 | $89K | Sell |
1,041
-1,005
| -49% | -$73.2K | ﹤0.01% | 5303 |
|
|
2014
Q3 | $129K | Sell |
2,046
-4,064
| -67% | -$217K | ﹤0.01% | 5130 |
|
|
2014
Q2 | $336K | Sell |
6,110
-116
| -2% | -$5.89K | ﹤0.01% | 4350 |
|
|
2014
Q1 | $246K | Sell |
6,226
-828
| -12% | -$35.4K | ﹤0.01% | 4595 |
|
|
2013
Q4 | $278K | Buy |
7,054
+6,341
| +889% | +$184K | ﹤0.01% | 4671 |
|
|
2013
Q3 | $17K | Sell |
713
-63
| -8% | -$2.2K | ﹤0.01% | 6603 |
|
|
2013
Q2 | $41K | Buy |
+776
| New | +$34K | ﹤0.01% | 6452 |
|
Other funds holding MACK
RA
JC
Barclays's MACK Position: Q2 2024 in Review
Barclays sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 7,348 shares — an estimated $109K sold.
Barclays first reported a position in MACK in Q2 2013 and held it in 33 quarters. The position peaked at $1.49M in Q1 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Barclays reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Barclays sold 7,348 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $109K.
- Barclays first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 33 quarters.
- Barclays's Merrimack Pharmaceuticals, Inc. position peaked at $1.49M in Q1 2015.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.